Evnin Luke 的 Form 4 申報
iTeos Therapeutics, Inc.（ITOS），2021/12/2 申報
- 申報編號
- 0001209191-21-067706
- 申報時間
- 2021/12/2 18:53 ET
- 交易日
- 2021/11/30-12/2
- 申報延遲
- 2 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
這份申報列了 7 筆非衍生性交易。公開市場賣出合計 $287.9 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Evnin LukeCIK 0001134657 | 持股 10% 以上大股東 |
| Foley ToddCIK 0001473930 | 持股 10% 以上大股東 |
| MPM BioVentures 2014, L.P.CIK 0001609492 | 持股 10% 以上大股東 |
| MPM BioVentures 2014 (B), L.P.CIK 0001609493 | 持股 10% 以上大股東 |
| MPM Asset Management Investors BV2014 LLCCIK 0001609495 | 持股 10% 以上大股東 |
| MPM Bioventures 2018 (B), L.P.CIK 0001729504 | 持股 10% 以上大股東 |
| MPM Asset Management Investors BV2018 LLCCIK 0001734817 | 持股 10% 以上大股東 |
| MPM BioVentures 2014 LLCCIK 0001765021 | 持股 10% 以上大股東 |
| MPM BioVentures 2014 GP LLCCIK 0001765091 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/11/30 | Common Stock | S賣出處分 | −5,861 | $34.62F3 | −$202,907.82 | 3,012,959 | 間接 | |
| 2021/11/30 | Common Stock | S賣出處分 | −28,076 | $35.19F6 | −$987,994.44 | 2,984,883 | 間接 | |
| 2021/12/1 | Common Stock | S賣出處分 | −6,042 | $33.82F9 | −$204,340.44 | 2,978,841 | 間接 | |
| 2021/12/1 | Common Stock | S賣出處分 | −5,457 | $34.61F12 | −$188,866.77 | 2,973,384 | 間接 | |
| 2021/12/1 | Common Stock | S賣出處分 | −896 | $35.34F15 | −$31,664.64 | 2,972,488 | 間接 | |
| 2021/12/2 | Common Stock | S賣出處分 | −29,757 | $33.74F18 | −$1,004,001.18 | 2,942,731 | 間接 | |
| 2021/12/2 | Common Stock | S賣出處分 | −7,430 | $34.83F21 | −$258,786.9 | 2,935,301 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.93 to $34.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.93 to $35.465 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.26 to $34.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F12
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.30 to $35.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F15
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.30 to $35.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F18
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.19 to $34.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F21
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $35.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
備註
See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.